Editas Medicine Announces Proposed Public Offering
Editas Medicine, a gene editing company listed on Nasdaq, announced the commencement of an underwritten public offering of its common stock and accompanying warrants. The offering is subject to market conditions and aims to raise capital to support its pipeline of CRISPR-based transformative medicines. Cantor and Wells Fargo Securities are managing…